C57BL/6J mice were immunized s.c. in one flank with 500 μg 1–20 RBP-3 peptide in water (2% DMSO) emulsified in CFA (1 mg/ml; 1:1 v/v) supplemented with 1.5 mg/ml Mycobacterium tuberculosis complete H37 Ra (BD Biosciences, Oxford, U.K.), and 1.5 μg Bordella pertussis toxin (Tocris, Bristol, U.K.) was given i.p.
Mycobacterium tuberculosis complete h37 ra
Manufactured by BD
Sourced in United Kingdom
The Mycobacterium tuberculosis complete H37 Ra is a laboratory-scale product used for research and development purposes. It provides a complete genomic sequence of the Mycobacterium tuberculosis H37 Ra strain, a commonly used avirulent variant of the Mycobacterium tuberculosis bacterium.
Automatically generated - may contain errors
6 protocols using mycobacterium tuberculosis complete h37 ra
1
Autoimmune Ophthalmic Disease Model
2
Induction of Experimental Autoimmune Uveitis
3
Autoimmune Ophthalmic Disease Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
C57BL/6J mice were immunized s.c. in one flank with 500 μg 1–20 RBP-3 peptide in water (2% DMSO) emulsified in CFA (1 mg/ml; 1:1 v/v) supplemented with 1.5 mg/ml Mycobacterium tuberculosis complete H37 Ra (BD Biosciences, Oxford, U.K.), and 1.5 μg Bordella pertussis toxin (Tocris, Bristol, U.K.) was given i.p.
4
Immunization and Intravitreal Infliximab Therapy for Experimental Autoimmune Uveitis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Female B10.RIII mice were immunized subcutaneously in one flank with 50 μg RBP-3161–180 in phosphate buffered saline (PBS) emulsified with Complete Freund’s Adjuvant (CFA) supplemented with 1.5 mg/ml Mycobacterium tuberculosis complete H37 Ra (BD Biosciences, Oxford, UK) (1:1 vol/vol). The mice also received 1 μg Bordetella pertussis toxin (Tocris, Bristol, UK) intraperitoneally (i.p.).
For local administration of infliximab or FpFinfliximab, intravitreal injections were performed on day 10 post-immunization. In brief, the eye was proptosed and held in position with a pair of forceps, while 15 μg of infliximab or FpFinfliximab diluted in 2 μl PBS was injected using a 33-gauge hypodermic needle (Esslab, Essex, UK). The injection site was treated with chloramphenicol and globe reposited.
For local administration of infliximab or FpFinfliximab, intravitreal injections were performed on day 10 post-immunization. In brief, the eye was proptosed and held in position with a pair of forceps, while 15 μg of infliximab or FpFinfliximab diluted in 2 μl PBS was injected using a 33-gauge hypodermic needle (Esslab, Essex, UK). The injection site was treated with chloramphenicol and globe reposited.
5
RBP-3 Peptide Immunization in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
C57BL/6 and B10RIII mice were immunised subcutaneously (s.c) in one flank with 50μg RBP-3 1–20 or 50μg RBP-3 161–180 respectively. Peptides were prepared in water (2% DMSO), emulsified in CFA (1mg/ml 1:1 v/v) and supplemented with 1.5mg.ml Mycobacterium tuberculosis complete H37 Ra (BD Biosciences, Oxford, U.K.). A simultaneous I.P injection of 1.5μg Bordella pertussis toxin (Tocris, Bristol, UK) was also administered. Doses of SB-435495, phosphate buffered saline (PBS) or vehicle solution were administered by I.P injection once or twice daily (9am or 9am/pm respectively) as described (S4 Fig ).
6
Mouse Model of Experimental Autoimmune Uveitis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
On Day 0, B10.RIII mice were immunized subcutaneously with 100 μL of recombinant human interphotoreceptor retinoid binding protein (IRBP) peptide (161–180) (1 mg/mL) emulsified 1:1 (v:v) in complete Freund's adjuvant containing 2.5 mg Mycobacterium tuberculosis complete H37Ra (BD Biosciences). After immunization, each mouse was injected with 1 μg of Bordetella pertussis toxin (Tocris Bioscience) intraperitoneally. Intraperitoneal administration of IOX1 (12.5 mg/kg) or DMSO solution was performed twice daily post-immunization. At peak disease (Day 14), mice were sacrificed, and tissues collected for ex-vivo analysis. To assess the clinical score of EAU, we used either a TEFI system22 (link) or a Micron IV murine fundus camera (Phoenix Research Labs, USA) and contemporaneous Spectralis-optical coherence tomography (OCT) scanning.23 The clinical scores were given by two independent experienced observers in a blindfold manner based on the criteria for EAU scoring as described previously.22 (link),23
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!